The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

GNCA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.61%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Genocea Biosciences Insider Trading History Chart

Genocea Biosciences Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 04/16/2024 01:00 AM ET

Days: 30 | 90 | 365

The Next Nvidia?

From InvestorPlace | Ad

Go here now for this breaking story.

Genocea Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/1/2022	Jacquelyn L Sumer	Insider	Sell	2,500	$0.06	$150.00	43,000
5/31/2022	William D Clark	CEO	Sell	117,244	$0.06	$7,034.64	308,400
5/26/2022	Diantha Duvall	CFO	Sell	24,407	$0.08	$1,952.56	76,743
5/25/2022	Ali Behbahani	Director	Sell	4,445,093	$0.08	$355,607.44
5/25/2022	Jessica Baker Flechtner	Insider	Sell	16,525	$0.09	$1,487.25	90,605
5/24/2022	Paul Edward Walker	Major Shareholder	Sell	5,931,843	$0.07	$415,229.01	4,445,093
4/4/2022	Diantha Duvall	CFO	Sell	963	$1.25	$1,203.75	91,775
4/4/2022	Jessica Baker Flechtner	Insider	Sell	1,212	$1.25	$1,515.00	68,330
4/4/2022	William D Clark	CEO	Sell	3,924	$1.25	$4,905.00	369,487
3/16/2022	Girish N Aakalu	Insider	Sell	2,397	$1.10	$2,636.70

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

SEC Filings (Institutional Ownership Changes) for Genocea Biosciences (NASDAQ:GNCA)

0.64% of Genocea Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Genocea Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/10/2022	Acadian Asset Management LLC	21,741	$25K	0.0%	N/A	0.038%
1/31/2022	Commonwealth Equity Services LLC	31,981	$37K	0.0%	+49.4%	0.056%
11/16/2021	Commodore Capital LP	3,079,756	$5.91M	1.6%	+5.1%	5.361%
11/15/2021	Point72 Asset Management L.P.	2,652,974	$5.09M	0.0%	+6.1%	4.618%
9/17/2021	Virtu Financial LLC	15,625	$37K	0.0%	N/A	0.029%
8/18/2021	Ikarian Capital LLC	200,000	$0.47M	0.0%	+153.9%	0.367%
8/17/2021	Millennium Management LLC	286,041	$0.67M	0.0%	+9.2%	0.525%
8/17/2021	Boothbay Fund Management LLC	23,095	$54K	0.0%	N/A	0.042%
8/16/2021	Point72 Asset Management L.P.	2,500,000	$5.85M	0.0%	N/A	4.593%
8/16/2021	Commodore Capital LP	2,929,447	$6.86M	2.4%	+2.0%	5.382%
8/16/2021	Diametric Capital LP	69,977	$0.16M	0.1%	N/A	0.129%
8/16/2021	State Street Corp	19,684	$46K	0.0%	N/A	0.036%
8/13/2021	Geode Capital Management LLC	179,714	$0.42M	0.0%	+3.6%	0.330%
8/13/2021	Vanguard Group Inc.	1,538,463	$3.60M	0.0%	-4.9%	2.826%
8/6/2021	Capital Asset Advisory Services LLC	11,766	$28K	0.0%	N/A	0.022%
5/18/2021	Millennium Management LLC	261,856	$0.71M	0.0%	+61.7%	0.481%
5/17/2021	Ikarian Capital LLC	78,767	$0.21M	0.0%	N/A	0.145%
5/13/2021	Renaissance Technologies LLC	25,659	$70K	0.0%	-93.5%	0.047%
5/10/2021	GSA Capital Partners LLP	80,876	$0.22M	0.0%	-38.1%	0.151%
5/7/2021	BlackRock Inc.	143,287	$0.39M	0.0%	+4.4%	0.268%
4/30/2021	Ground Swell Capital LLC	13,616	$37K	0.1%	N/A	0.025%
4/14/2021	WealthTrust Axiom LLC	15,000	$40K	0.0%	N/A	0.028%
4/12/2021	FNY Investment Advisers LLC	190,000	$0.51M	0.2%	-5.0%	0.355%
2/12/2021	Personal Capital Advisors Corp	15,000	$36K	0.0%	N/A	0.029%
2/10/2021	Renaissance Technologies LLC	395,763	$0.96M	0.0%	+87.8%	0.766%
2/4/2021	GSA Capital Partners LLP	130,745	$0.32M	0.1%	N/A	0.253%
11/17/2020	Jane Street Group LLC	14,508	$33K	0.0%	N/A	0.028%
11/17/2020	Boxer Capital LLC	1,134,453	$2.60M	0.1%	N/A	2.197%
11/16/2020	Squarepoint Ops LLC	25,966	$59K	0.0%	-80.4%	0.050%
11/12/2020	Polaris Venture Management Co. V L.L.C.	197,345	$0.45M	0.7%	-19.8%	0.382%
11/6/2020	NEA Management Company LLC	10,376,936	$23.76M	1.0%	+43.6%	34.631%
11/6/2020	BlackRock Inc.	135,067	$0.31M	0.0%	-30.8%	0.451%
11/3/2020	Johnson & Johnson Innovation JJDC Inc.	43,177	$99K	0.0%	-70.0%	0.144%
10/30/2020	WINTON GROUP Ltd	11,951	$27K	0.0%	-58.3%	0.040%
10/9/2020	FNY Investment Advisers LLC	200,000	$0.46M	0.2%	-33.3%	0.667%
8/14/2020	BVF Inc. IL	2,018,398	$4.64M	0.3%	-3.9%	6.736%
8/7/2020	Virtu Financial LLC	36,686	$84K	0.0%	N/A	0.122%
8/5/2020	WINTON GROUP Ltd	28,655	$66K	0.0%	+63.4%	0.096%
7/16/2020	Wedbush Securities Inc.	45,515	$0.11M	0.0%	N/A	0.165%
5/11/2020	WINTON GROUP Ltd	17,538	$30K	0.0%	N/A	0.063%
5/6/2020	Bank of New York Mellon Corp	20,266	$35K	0.0%	N/A	0.073%
5/6/2020	NEA Management Company LLC	7,225,676	$12.43M	0.6%	N/A	26.142%

Data available starting January 2016

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

83,499 shs

Market Capitalization

$6,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Who are the company insiders with the largest holdings of Genocea Biosciences?: Genocea Biosciences' top insider investors include:
Paul Edward Walker (Major Shareholder)
William D Clark (CEO)
Jessica Baker Flechtner (Insider)
Diantha Duvall (CFO)
Jacquelyn L Sumer (Insider)
Ali Behbahani (Director)
Learn More about top insider investors at Genocea Biosciences.